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A B S T R A C T
Background
Surgery is an important part of the management of oral cavity cancer with regard to both the removal of the primary tumour and
removal of lymph nodes in the neck. Surgery is less frequently used in oropharyngeal cancer. Surgery alone may be treatment for
early stage disease or surgery may be used in combination with radiotherapy, chemotherapy and immunotherapy/biotherapy. There is
variation in the recommended timing and extent of surgery in the overall treatment regimens of people with these cancers.
Objectives
To determine which surgical treatment modalities for oral cavity and oropharyngeal cancers result in increased overall survival, disease
free survival, progression free survival and reduced recurrence.
Search methods
The following electronic databases were searched: the Cochrane OralHealth Group Trials Register (to 17 February 2011), the Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1), MEDLINE via OVID (1950 to 17 February
2011) and EMBASE via OVID (1980 to 17 February 2011). There were no restrictions regarding language or date of publication.
Selection criteria
Randomised controlled trials where more than 50% of participants had primary tumours of the oral cavity or oropharynx, and which
compared two or more surgical treatment modalities or surgery versus other treatment modalities.
Data collection and analysis
Data extraction and assessment of risk of bias was undertaken independently by two or more review authors. Study authors were
contacted for additional information as required. Adverse events data were collected from published trials.
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Main results
Seven trials (n = 669; 667 with cancers of the oral cavity) satisfied the inclusion criteria, but none were assessed as low risk of bias.
Trials were grouped into three main comparisons. Four trials compared elective neck dissection (ND) with therapeutic neck dissection
in patients with oral cavity cancer and clinically negative neck nodes, but differences in type of surgery and duration of follow-up
made meta-analysis inappropriate. Three of these trials reported overall and disease free survival. One trial showed a benefit for elective
supraomohyoid neck dissection compared to therapeutic ND in overall and disease free survival. Two trials found no difference between
elective radical ND and therapeutic ND for the outcomes of overall survival and disease free survival. All four trials found reduced
locoregional recurrence following elective ND.
A further two trials compared elective radical ND with elective selective ND and found no difference in overall survival, disease free
survival or recurrence. The final trial compared surgery plus radiotherapy to radiotherapy alone but data were unreliable because the
trial stopped early and there were multiple protocol violations.
None of the trials reported quality of life as an outcome. Two trials, evaluating different comparisons reported adverse effects of
treatment.
Authors’ conclusions
Seven included trials evaluated neck dissection surgery in patients with oral cavity cancers. The review found weak evidence that elective
neck dissection of clinically negative neck nodes at the time of removal of the primary tumour results in reduced locoregional recurrence,
but there is insufficient evidence to conclude that elective neck dissection increases overall survival or disease free survival compared to
therapeutic neck dissection. There is very weak evidence from one trial that elective supraomohyoid neck dissection may be associated
with increased overall and disease free survival. There is no evidence that radical neck dissection increases overall survival compared to
conservative neck dissection surgery. Reporting of adverse events in all trials was poor and it was not possible to compare the quality
of life of patients undergoing different surgeries.
P L A I N L A N G U A G E S U M M A R Y
Surgical interventions for the treatment of oral cavity (mouth) and oropharyngeal (throat) cancers
The studies in this review focused on patients with cancers in the oral cavity. These studies have not shown that surgery to remove the
lymph nodes in the neck, which appear to be cancer-free, at the same time as the cancer is removed is associated with longer survival,
but there is evidence that early neck surgery reduces recurrence of the cancer. Neither is there evidence that removal of all the lymph
nodes in the neck results in longer survival compared to selective surgical removal of affected lymph nodes. Although removal of lymph
nodes from the neck is associated with significant adverse effects related to appearance and functions such as eating, drinking and
speaking, the studies in this review did not measure quality of life.
B A C K G R O U N D
Oral cancers are a significant disease group globally with more
than 404,000 new cases worldwide in 2002 (Parkin 2005;
Warnakulasuriya 2009). Oral cancers are the sixth most common
cancer worldwide, accounting for an estimated 4% of all cancers.
The incidence and mortality from oral cancers varies geographi-
cally; the highest age standardised rates of oral cancers are reported
in parts of Europe (France, Hungary), Botswana and south central
Asia (Sri Lanka, Pakistan, Banglasdesh and India) (Parkin 2005).
There is overwhelming evidence that tobacco use, alcohol con-
sumption and betel quid chewing are the main risk factors in the
aetiology of intraoral cancer (La Vecchia 1997; Macfarlane 1995).
There is also strong evidence that low socio-economic status is
associated with a higher incidence and poorer survival of oral can-
cers (Faggiano 1997). There is a higher incidence of oral cancers
in men (Freedman 2007) that is generally attributed to a greater
exposure to the known risk factors and vast majority of cases occur
in men over 50 (Warnakulasuriya 2009) and among low socio-
economic groups (Conway 2008). However, the ratio of males to
females diagnosed with oral cancers has declined from approxi-
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mately 5:1 in the 1960s to less than 2:1 in 2002 (Parkin 2005).
Another recent trend is the increasing incidence of oral cavity and
oropharyngeal cancers in younger adults in the European Union
and the United States (Warnakulasuriya 2009).
The epidemiological data concerning ’oral cancer’ obscures the
fact that ’oral cancer’ includes both oral cavity and oropharyn-
geal cancers which have clinically different aetiology, are gener-
ally diagnosed at different stages and managed in different ways.
In the past, clinical trials have recruited patients with head and
neck cancers as if this was a single disease entity (Adelstein 2009).
However patients with oral cavity cancers generally present with
early stage disease and the primary treatment is surgery or radio-
therapy or both. Oropharyngeal cancers are likely to be advanced
at the time of diagnosis and primary treatment for these patients
is more likely to be radiation therapy or chemoradiation. It is now
recognised that oral infection with human papilloma virus (HPV)
is strongly associated with the development of oropharyngeal can-
cer where HPV infection is found in 40% to 60% of patients,
especially younger male patients (Adelstein 2009; D’Souza 2007),
and HPV is associated with the increased incidence of oropharyn-
geal cancer (Adelstein 2009; Hammarstedt 2006). The link be-
tween oncogenic HPV and oropharyngeal cancer is strong and has
been documented in numerous studies, fulfilling the epidemiolog-
ical criteria for disease causality, especially in the development of
oropharyngeal cancer in non-smokers (Sturgis 2007). The propor-
tion of patients with oropharyngeal cancer who are HPV positive
has increased dramatically over recent years (Attner 2010; Ryerson
2008) but it is interesting to note that this group of patients have
significantly improved rates of both overall survival and disease
free survival (Adelstein 2009; Fakhry 2006; Fakhry 2008; Licitra
2006).
The most common cancer of the oral cavity is the squamous cell
carcinoma that arises from the lining of the oral cavity; over 95%
of all oral cavity cancers are squamous cell carcinomas. Despite
significant technical advances in the treatment of oral cancer, it
still has a significant mortality with 128,000 deaths recorded, rep-
resenting nearly half of the incident cases (48%) (Parkin 2001).
Survival following a diagnosis of oral cavity or oropharyngeal can-
cer remains poor with 5-year survival around 50% overall, with
only limited improvement in the past 3 decades (Warnakulasuriya
2009).
Description of the intervention
Surgery can be combined with any combination of radiotherapy,
chemotherapy and immunotherapy/biotherapy; the sequence of
these combination therapies is also considered important. Radio-
therapy is typically now administered postoperatively. Chemo-
therapy can be given: i) before surgery (induction/neoadjuvant -
when treatment is administered before the primary therapy, e.g. it
is used to shrink a tumour prior to surgery or radiation); ii) after
surgery (adjuvant - cancer treatment that is administered after the
primary therapy, e.g. when the primary therapy to treat a can-
cerous tumour is surgery, chemotherapy would be considered an
adjuvant therapy) and before radiotherapy; iii) at the same time
as radiotherapy (concomitant/concurrent - it may also be referred
to as chemo/radiotherapy); or iv) alternating with radiotherapy.
The locoregional control of the primary tumour is the main crite-
rion of successful treatment. Tumours are excised with a margin of
clinically normal tissue (this can be typically a margin of between
1 and 2 centimetres in the UK). Despite this apparent complete
clinical surgical excision, the tumour may still be demonstrated at
the margins histopathologically; this has prognostic implications
(Batsakis 1999; Sutton 2003). Margins apparently histologically
free of tumour may demonstrate molecular changes and the pres-
ence of such tumour clonogen populations at the margins may be
predictive for disease progression (Partridge 2000).
Spread of the tumour to the regional lymph nodes within the neck
(cervical nodes) is an early and consistent event in the natural
history of oral and oropharyngeal cancers (Haddadin 2000). The
extent of cervical involvement is reflected in the staging of the
tumour and has prognostic implications (Shah 1990). Therefore,
surgical dissection of the cervical lymph nodes at risk of metas-
tasis may be undertaken as part of the management of the pri-
mary tumour. The classic radical neck dissections removed all of
the cervical lymph nodes from levels I to V combined with the
sternocleidomastoid muscle, internal jugular vein, submandibu-
lar gland and the spinal accessory nerve with resultant significant
postoperative morbidity. This is now only reserved for advanced
neck disease.Modifications of the neck dissection to preserve some
or all of the associated structures have reduced morbidity and may
now be undertaken as selective neck dissections (Carew 2003;
Robbins 2002). There has been an increasing trend in using the
selective neck dissection as a therapeutic procedure in the clini-
cally N0 neck (nodal status - no palpable nodes). In addition to
the extent of neck disease at presentation, spread of the tumour
out with the capsule of the lymph nodes (extracapsular spread)
has also been shown to be a poor prognostic indicator (Woolgar
2003). Historically clinicians treating oral cancer have not focused
on distant metastatic disease. This has been because locoregional
control had been the main cause of death and there were also less
effective chemotherapeutic agents to deal with distant metastases.
With improvements in locoregional control distant metastases are
an increasing issue in the management of oral cancer.
When small tumours (T1, less than2 centimetres orT2, 2 to 4 cen-
timetres) present with apparently clinically negative neck nodes,
there is controversy over the management of the cervical lymph
nodes (Woolgar 2003). Studies have demonstrated an improved
outcome when a neck dissection has been undertaken at the same
time as the resection of the primary tumour rather than waiting
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for neck disease to present subsequently (Haddadin 2000;Hughes
1993) although others adopt a ’wait and see’ policy. In cancer of
the tongue the thickness of the tumour reflects the risk of nodal
metastasis (Pentenero 2005).
Why it is important to do this review
The management of advanced oral cavity and oropharyngeal can-
cers is problematic and has traditionally relied on surgery and ra-
diotherapy, both of which are associated with substantial adverse
effects. Although there have been new treatments developed there
has been limited improvement in survival over the past 3 decades
(Warnakulasuriya 2009). Oropharyngeal cancers have relatively
’silent’ symptoms which may not be present during the early stages
of the disease, which is a possible explanation for the fact that
stage of disease at diagnosis has not altered in the past 40 years
despite public education (McGurk 2005). Tumour recurrence and
the development ofmultiple primary tumours are themajor causes
of treatment failure (Day 1992; Partridge 2000; Woolgar 2003).
Surgical treatment may be disfiguring and result in a substantially
reduced quality of life as patients are socially isolated, due to diffi-
culties with altered appearance, speech, eating and drinking. De-
velopments in the way in which surgery is delivered aim to im-
prove its efficacy and reduce the impact on patients’ quality of life.
This review is undertaken as part of a series of reviews looking at
the different treatment modalities of oral cancer (Furness 2011;
Glenny 2010). These reviews have been categorised into four in-
tervention groups: surgery, chemotherapy, radiotherapy and im-
munotherapy. For this surgical review we will aim to answer the
broad questions ’Does surgery, in addition to chemotherapy and/
or radiotherapy, improve the outcomes for patients with oral cavity
and oropharyngeal cancers?’ and ’Which type of surgery improves
the outcomes for patients with oral cavity and oropharyngeal can-
cers?’.
For this surgical review we will include all randomised controlled
trials where more than 50% of participants included have primary
tumours in the oral cavity or oropharynx. Only trials where pa-
tients in each treatment arm receive different surgical interventions
(either different techniques or timing), or radiotherapy and/or
chemotherapy plus or minus surgery, or surgery versus no surgery
will be included.
O B J E C T I V E S
Primary objective
To determine which surgical treatment modalities for oral and
oropharyngeal cancers result in increased overall survival, disease
free survival, locoregional control and reduced recurrence.
Secondary objective
To determine the implication of treatment modalities in terms of
morbidity, quality of life, costs, hospital days of treatment, com-
plications and harms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing different surgical
treatmentmodalities or trials of other treatment interventionswith
and without surgery including radiotherapy and chemotherapy
were included in the review. It is anticipated that there will be no
studies comparing surgery with placebo (although if there are such
studies they will be included).
Types of participants
Patients with oral cancer as defined by the International Classifica-
tion of Diseases for Oncology (ICD-O) codes as C01-C02, C03,
C04, C05-C06 (oral cavity) and cancer of the oropharynx (ICD-
O: C09, C10) will be included but hypopharynx (ICD-O: C13),
nasopharynx (ICD-O: C11) and larynx (ICD-O: C32) will be
excluded. Cancers of the lip (ICD-O: C00) will also be excluded
(WHO 1990).
Studies of head and neck cancer with cases of oral cancer will be
included (so long as at least 50% of participants have oral cavity or
oropharyngeal cancer, or data for these cancers alone is available
separately).
Cancers will be primary squamous cell carcinomas arising from
the oralmucosa.Histological variants of squamous cell carcinomas
will be included (adenosquamous, verrucous, basaloid, papillary
etc) although they are known to have differing natural history to
the majority of conventional squamous cell carcinomas they have
a common aetiology, their incidence is low and they are generally
managed in the same way. Carcinoma in situ will be included. Ep-
ithelial malignancies of the salivary glands, odontogenic tumours,
all sarcomas and lymphomas will be excluded as these have a dif-
ferent aetiology and are managed differently.
Types of interventions
Surgical treatment of the primary tumour is typically one of the
primary treatment interventions. Surgical treatment could include
traditional scalpel based surgery, laser cutting or ablation, or har-
monic scalpel. Surgical treatment could have been compared to
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other surgical interventions, or to different treatment modalities
such as radiotherapy, chemotherapy, immunotherapy/biotherapy
with or without surgery; any combinations were considered pro-
viding they were compared to surgery in at least one arm of the
study. Salvage surgery and palliative surgery were not considered
in this review.
Surgical treatment of the neck lymph nodes (cervical lymph nodes)
could have preceded, occurred simultaneously with or subsequent
to the surgical treatment of the primary tumour. When there was
no treatment of the primary tumour but only surgical treatment of
the cervical lymphnodes these studieswere not considered. Studies
concerned with cervical lymph node management in the surgical
treatment of the primary tumour were included. The treatments
received and compared must have been the primary treatment
for the tumour and patients should not have received any prior
intervention other than diagnostic biopsy.
Types of outcome measures
Primary outcome measures
• Overall survival / total mortality (disease related mortality
will also be studied if possible)
• Disease-free survival
• Local regional control
• Recurrence
Secondary outcome measures
• Harms associated with treatment
• Quality of life
• Direct and indirect costs to patients and health services
• Patient satisfaction
Search methods for identification of studies
This review is part of a series of Cochrane reviews on the treatment
modalities for treating oral cavity and oropharyngeal cancer. The
reviews have been broadly divided into four themes concerning:
surgery, chemotherapy, radiotherapy or immunotherapy/targeted
therapies. A search strategy was developed that would encompass
three of the four broad themes simultaneously (surgery, chemo-
therapy, radiotherapy) and further adapted for use in the following
databases (date of the most recent searches as indicated):
• MEDLINE via OVID (1950 to 17 February 2011)
(Appendix 1);
• The Cochrane Oral Health Group’s Trials Register (to 17
February 2011) (Appendix 2);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, 2011, Issue 1) (Appendix
3);
• EMBASE via OVID (1980 to 17 February 2011)
(Appendix 4).
As studies involving oral cancer are often included with those of
the head and neck, a broad search was undertaken to include all
possible studies. The searches attempted to identify all relevant
trials irrespective of language. Papers not in English were data ex-
tracted/translated by members of The Cochrane Collaboration.
Trials were excluded if it was not possible to translate them into
the English language. The reference lists of relevant articles were
searched and authors were contacted in order to identify unpub-
lished or ongoing trials.
Sensitive search strategies were developed for each database using a
combination of free text andMeSH terms; these were based on the
search strategy developed forMEDLINE (Appendix 1) but revised
appropriately for each database. The search strategy combined the
subject search with the Cochrane Highly Sensitive Search Strategy
(CHSSS) for identifying randomised trials in MEDLINE: sensi-
tivity maximising version (2009 revision) as referenced in Chapter
6.4.11.1 and detailed in box 6.4.c of the Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated March
2011) (Higgins 2011). The search of EMBASE was linked to the
Cochrane Oral Health Group filter for identifying RCTs in this
database (Appendix 4). Only handsearching carried out by The
Cochrane Collaboration is included in the search (see master list
www.cochrane.org).The reference lists of related reviews and all
articles obtained were checked for further trials. Authors of trial re-
ports and specialists in the field known to the review authors were
written to concerning further published and unpublished trials.
Data collection and analysis
Selection of studies
The titles and abstracts (when available) of all reports identified
through the electronic searches were scanned independently by
two review authors. For studies appearing to meet the inclusion
criteria, or for which there are insufficient data in the title and
abstract to make a clear decision, the full report was obtained. The
full reports obtained from all the electronic and other methods of
searching were assessed independently by two review authors to
establish whether the studies meet the inclusion criteria or not.
Disagreements were resolved by discussion. Where resolution was
not possible, a third review author was consulted. All studies meet-
ing the inclusion criteria underwent a risk of bias assessment and
data extraction using a specially designed data extraction form.
Studies rejected at this or subsequent stages were recorded in the
’Characteristics of excluded studies’ table, and reasons for exclu-
sion recorded.
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Data extraction and management
Data were extracted by two review authors independently using
specially designeddata extraction forms.The data extraction forms
were piloted on several papers and modified as required before
use. Any disagreements were discussed and a third review author
consulted where necessary. However, group discussion was often
required following data extraction due to the complexity of the
data presented. When necessary, authors were contacted for clari-
fication or missing information.
For each trial the following data were recorded.
• Year of publication, country of origin and source of study
funding.
• Details of the participants including demographic
characteristics and criteria for inclusion and exclusion,
proportion with oral cavity and oropharyngeal cancer.
• Details of the type of intervention, timing and duration.
• Details of the outcomes reported, including method of
assessment, and time intervals.
Head and neck cancer trials with only combined data (i.e. no
outcome data available by primary tumour site) where greater
than 50% of participants presented with oral/oropharyngeal can-
cer were planned to be included in this review. However, where
separate ’pure’ oral/oropharyngeal cancer data were available for a
trial, these ’pure’ data were extracted and analysed and the com-
bined head and neck data ignored.
Assessment of risk of bias in included studies
For the studies included in this review, assessment of risk of bias
was conducted independently by at least two review authors using
the Cochrane risk of bias assessment tool (Higgins 2011). We as-
sessed six domains for each included study: sequence generation,
allocation concealment, blinding (of patient, carer, outcome as-
sessor), completeness of outcome data, risk of selective outcome
reporting and risk of other potential sources of bias. An overall
risk of bias assessment was also made.
For this systematic review we assessed risk of bias according to the
following.
• Sequence generation: use of a random number table, use of
a computerised system, central randomisation by statistical co-
ordinating centre, randomisation by an independent service
using minimisation technique, permuted block allocation or
Zelan technique. If the paper merely stated randomised or
randomly allocated with no further information this was assessed
as being unclear.
• Allocation concealment: centralised allocation including
access by telephone call or fax, or pharmacy-controlled
randomisation, sequentially numbered, sealed, opaque envelopes.
• Blinding: unless the trial was specifically described as
double blind, or there was a statement about blinding in the
methods section of the paper it was assumed that blinding of
patients, clinical staff and outcome assessors did not occur due to
lack of feasibility.
• Outcome data: outcome data were considered complete if
all patients randomised were included in the analysis of the
outcome(s). However, in trials of treatment for cancer this is
rarely the case. Trials where less than 10% of those randomised
were excluded from the analysis, and where reasons for
exclusions were described for each group, and where both
numbers and reasons were similar in each group, were assessed as
being at low risk of bias due to incomplete outcome assessment.
Where post-randomisation exclusions were greater than 10%, or
reasons were not given for exclusions from each group, or where
rates and reasons were different for each group, the risk of bias
due to (in)complete outcome data was assessed as unclear.
• Selective outcome reporting: a trial was assessed as being at
low risk of bias due to selective outcome reporting if the
outcomes of interest described in the methods section, were
systematically reported in the results section. Where reported
outcomes did not include those outcomes specified or expected
in trials of treatments for oral cancer, or where additional
analyses were reported this domain was assessed as unclear.
• Other bias: imbalance in potentially important prognostic
factors between the treatment groups at baseline, or the use of a
co-intervention in only one group (for example nasogastric
feeding) are examples of potential sources of bias noted.
Measures of treatment effect
The primary outcome is total mortality expressed as a hazard ratio
(it is acknowledged that it is preferable to talk in terms of overall
survival, however, statistically the estimate of effect is the hazard
ratio of death). These data were entered into the meta-analysis
using the inverse variancemethod. If hazard ratios were not quoted
in studies, we calculated the log hazard ratio and the standard
error (SE) from the available summary statistics or Kaplan-Meier
curves, according to themethods proposed by Parmar et al (Parmar
1998), or these data were requested from authors.
For dichotomous outcomes, the estimates of effect of an interven-
tion were expressed as risk ratios together with 95% confidence
intervals. Dichotomous data were only used for primary outcomes
where hazard ratios were unavailable or could not be calculated.
Assessment of heterogeneity
Meta-analyses were conducted only if there were studies of similar
comparisons reporting the same outcome measures. The signifi-
cance of any discrepancies in the estimates of the treatment effects
from the different trials was assessed by means of Cochran’s test
for heterogeneity and the I² statistic, and any heterogeneity inves-
tigated.
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Data synthesis
Meta-analyses were conducted only if there were studies of sim-
ilar comparisons reporting the same outcome measures. Risk ra-
tios were combined for dichotomous data, and hazard ratios for
survival data, using a fixed-effect model, unless there were more
than four trials to be combined, when a random-effects model was
used.
Subgroup analysis and investigation of heterogeneity
Due to the different natural history and treatment regimens for
oral cavity and oropharyngeal cancers we planned to analyse these
cancer types separately if possible.
Sensitivity analysis
A sensitivity analysis (to examine the effects of randomisation, allo-
cation concealment, blinded outcome assessment (if appropriate)
and quality of follow-up/completeness of data set) was planned
but there were insufficient data.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Over 2940 research papers were identified through the electronic
searching. Screening of the titles and abstracts resulted in the iden-
tification of 32 potentially relevant trials for inclusion in the re-
view. Full text copies of these articles were retrieved, and assessed
further. Further assessment of the papers resulted in seven trials
being included in this update of the review. Two of these trials
were newly identified (BHNCSG 1998; Yuen 2009).
Included studies
Of the seven trials included in the review, five were multicentred,
with the number of centres ranging from two to 12. One trial was
undertaken in India (Fakih 1989), two in Brazil (BHNCSG 1998;
Kligerman 1994), one in centres across Europe (Austria, Ger-
many and Switzerland) (Bier 1994), one in France (Vandenbrouck
1980), one in China (Yuen 2009) and one in the UK (Robertson
1998). Twenty-four trials, previously included in this review, have
now been excluded, because they better fit in the other oral can-
cer treatment reviews (see Characteristics of excluded studies for
details).
Characteristics of the Trial Participants
Participants were recruited over periods ranging from 2 years
to 7 years, with the earliest recruitment commencing in 1966
(Vandenbrouck 1980). A total of 669 patients were randomly al-
located to treatments and 570 were included in the outcome eval-
uations. Only two of the trial participants had oropharyngeal tu-
mours and all the remainder had oral cavity tumours.
Tumour extent (TNM) was reported in all of the included trials,
three of which included patients with T1 to T2 tumours (Fakih
1989; Kligerman 1994; Yuen 2009), two with T2 to T4 tumours
(BHNCSG 1998; Robertson 1998) and one with T1 to T3 tu-
mours (Vandenbrouck 1980). In five of the trials participants
had clinically negative neck nodes (BHNCSG 1998; Fakih 1989;
Kligerman 1994; Vandenbrouck 1980; Yuen 2009) and one trial
included participants with neck nodes clinically staged as N0-2
(Robertson 1998). The trial by Bier 1994 did not record the tu-
mour stage or node status of the participants at trial entry (Table
1).
Of the seven included trials, six included recruited participants
with oral cavity cancer only (BHNCSG 1998; Bier 1994; Fakih
1989; Kligerman 1994; Vandenbrouck 1980; Yuen 2009) and a
further one included thosewith oral cavity or oropharyngeal cancer
(Robertson 1998).
Characteristics of the Interventions
None of the included trials compared different surgical approaches
to the excision of the primary tumour.
The six trials of participants with oral cavity cancers all compared
different surgical techniques for management of the lymph nodes
in the neck (BHNCSG 1998; Bier 1994; Fakih 1989; Kligerman
1994; Vandenbrouck 1980; Yuen 2009). Four trials compared
the timing of neck dissection; either elective neck dissection at
the same time as excision of the primary tumour or therapeutic
neck dissection (delayed until nodes became clinically positive)
(Fakih 1989; Kligerman 1994; Vandenbrouck 1980; Yuen 2009).
Kligerman 1994 used a supraomohyoid approach for the elective
neck dissection in a group of patients with clinically negative neck
nodes and in Yuen 2009 elective selective neck dissection at the
time of glossectomy was compared with glossectomy alone plus
therapeutic neck dissection if nodes became clinically positive. In
the trial by Fakih 1989, elective radical neck dissection was used at
the same time as resection of the primary tumour in a group with
clinically negative neck nodes. In Vandenbrouck 1980, elective
radical neck dissectionwithin 2months of resection of the primary
tumour, was compared with therapeutic neck dissection.
Two trials compared different types of neck dissection surgery. In
the trial by Bier 1994 both groups had a radical resection of the
primary tumour. One group had radical neck dissection at the
same time as resection and the other had selective neck dissection
surgery. The Brazilian Study group (BHNCSG 1998) compared a
modified radical neck dissection at the time of primary resection of
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the tumour, with a supraomohyoid neck dissection in conjunction
with resection of the primary tumour.
The trial by Robertson 1998 compared surgery followed by radio-
therapy with radiotherapy alone in a group of patients with either
oral cavity or oropharyngeal cancer.
Characteristics of outcome measures
The duration of follow-up in the included trials ranged from ap-
proximately 15 months (Bier 1994) to 122 months (Yuen 2009).
All trials except one (Yuen 2009) reported either total mortality or
overall survival but not all provided data in a form suitable for in-
clusion in meta-analysis. Disease free survival was reported in four
trials (Fakih 1989; Kligerman 1994; Vandenbrouck 1980; Yuen
2009) and recurrence was reported in five trials (BHNCSG 1998;
Fakih 1989; Kligerman 1994; Robertson 1998; Yuen 2009).
Harms/adverse events were mentioned in two trials (BHNCSG
1998; Robertson 1998). BHNCSG 1998 reported the total num-
ber of adverse events in each group but not the number of patients
affected and Robertson 1998 reported the percentages of partici-
pants in each group who experienced adverse effects.
The following outcomes were not reported in any of the included
studies:
• hospital days of treatment
• quality-adjusted-life-years (QALYs)
• costs.
Excluded studies
Twenty-four trials, previously included in this review, have now
been excluded because they better fit in the other oral cancer treat-
ment reviews. Four previously included trials (Ang 2001; Lawrence
1974; Sanguinetti 2005; Terz 1981), are now included in the ra-
diotherapy review (Glenny 2010); 17 previously included trials
(Bernier 2004; Cooper 2004; Lam 2001; Laramore 1992; Licitra
2003; Luboinski 1985; Maipang 1995; Mohr 1994; Paccagnella
1994; Rao 1991; Rentschler 1987; Richard 1991; Schuller 1988;
Szabo 1999; Szpirglas 1978; Volling 1999;Weissler 1992) are now
included in the chemotherapy review (Furness 2011), and 3 pre-
viously included trials are being considered for inclusion in the
immunotherapy review which is currently being prepared. One
trial was excluded from this review because less than 50% of the
participants had oral cavity of oropharyngeal cancer and their data
could not be extracted separately (Hintz 1979a).
Risk of bias in included studies
Allocation
Two of the included trials reported adequate sequence generation
methods (Fakih 1989; Robertson 1998) and in the remaining five
trials the methods of sequence generation were unclear. Adequate
allocation concealment was reported in two trials also (Robertson
1998; Vandenbrouck 1980), but only one trial was assessed as
being at low risk of bias in both of these domains (Robertson
1998).
Blinding
Blinding of participants and clinicians is not feasible in surgical
trials, but blinding of outcome assessment is both possible and
desirable. A decision was made to assess those trials which do not
explicitly report blinding of outcome assessors, as being at unclear
risk of bias for this domain. None of the included studies reported
that outcome assessors were blinded to allocated treatment group.
It was felt that for objective outcomes (such as total mortality) the
lack of blinding was unlikely to result in bias. However, for more
subjective outcomes, such as disease free survival, lack of blinding
was considered to represent a potential risk of bias.
Incomplete outcome data
Five of the included trials were assessed as being at low risk of
bias with regard to incomplete outcome data (BHNCSG 1998;
Kligerman 1994; Robertson 1998; Vandenbrouck 1980; Yuen
2009) because all the randomised participants were adequately ac-
counted for in the outcome evaluation. The remaining trials (Bier
1994; Fakih 1989) were assessed as at high risk with regard to this
domain. Both Bier 1994 and Fakih 1989 present an interim analy-
sis of a subgroup of participants and the final analysis has not been
published as far as we are aware. In both of these trials it is un-
clear how many participants were randomly allocated to each in-
tervention group, and howmany in each group were subsequently
excluded from the analysis and/or analysed in a different group
from that to which they were originally allocated. It is likely that
those excluded from the analysis (because they refused surgery or
had extracapsular rupture during surgery) had a different outcome
from those included in the analysis.
Selective reporting
Six of the included trials were assessed as being free of selective
reporting bias, reporting on expected, clinically important out-
comes. Yuen 2009 did not report total mortality or overall sur-
vival, so was assessed at high risk of bias for this domain.
Other potential sources of bias
Three trials, (BHNCSG 1998; Vandenbrouck 1980; Yuen 2009)
were assessed at low risk of other bias because the intervention
groups appeared to be similar at baseline and no other sources of
bias were identified.
Three trials (Bier 1994; Fakih 1989; Kligerman 1994) provided no
information regarding the baseline characteristics of participants
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in each group, and so these trials were assessed as being at unclear
risk of other bias.
Robertson 1998 was assessed at high risk of other bias because
although planned recruitment was 350 patients, this trial was
stopped after only 35 patients were recruited because clinicians felt
it was unethical to continue. While appropriate procedures were
followed and an interim analysis was conducted and reported, it
is not clear from this report whether a priori stopping rules were
in place. Additionally more than half of the patients in this trial
did not receive radiotherapy as planned due to problems with the
equipment breaking down. It is likely that this would have had a
greater effect on the outcomes the of radiotherapy-only arm of the
trial.
Overall risk of bias
A summary of the Risk of Bias assessment is presented in Figure
1. Overall we assessed four studies to be at high risk of bias (Bier
1994; Fakih 1989; Robertson 1998; Yuen 2009) and three trials
to be at unclear risk of bias (BHNCSG 1998; Kligerman 1994;
Vandenbrouck 1980) for all of the outcomes evaluated.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
Comparison 1: Elective neck dissection versus
therapeutic delayed neck dissection
Four trials (Fakih 1989; Kligerman 1994; Vandenbrouck 1980;
Yuen 2009) in this comparison compared the timing of the neck
dissection; either at the same time as resection of the primary
tumour or as a separate procedure subsequent to resection of the
primary, with dissection of the neck nodes being undertaken only
after there was clinical evidence of disease in the neck nodes. All
participants had oral cavity cancers, specifically tongue or floor
of mouth tumours and clinically negative neck nodes on study
entry. There were differences between the trials in the surgical
procedures and in the duration of follow-up so meta-analysis was
not undertaken.
Fakih 1989 and Vandenbrouck 1980 performed classical radical
neck dissection procedures and data are reported after 1 year and 3
years of follow-up in these two trials respectively. Yuen 2009 per-
formed selective neck dissection of level I to III nodes. Kligerman
1994 used a supraomohyoid (SOH) elective neck dissection pro-
cedure, and reported data after 3.5 years of follow-up. Fakih 1989
and Yuen 2009 were assessed as being at high risk of bias and
Kligerman 1994 and Vandenbrouck 1980 were at unclear overall
risk of bias.
Two of the three trials, which reported overall survival and dis-
ease free survival found no difference between elective radical
neck dissection and therapeutic neck dissection (Fakih 1989;
Vandenbrouck 1980) for either of these outcomes (Analysis 1.1;
Analysis 1.2; Analysis 1.4). However in the trial by Kligerman
1994, where elective surgery was the less extensive SOH, there was
a difference in both overall survival and disease free survival after
3.5 years of follow-up, favouring elective SOH neck dissection
compared to therapeutic neck dissection (Analysis 1.1; Analysis
1.3). Yuen 2009 did not report either total mortality or disease
free survival.
There is some evidence that elective neck resection appears to
reduce locoregional recurrence rates from all of the four studies but
the data was not suitable for meta-analysis due to the differences
between studies in the type of surgery and the duration of follow-
up (Analysis 1.5).
Two of these trials (Vandenbrouck 1980; Yuen 2009) reported
recurrence rates at different sites, but numbers were too small to
determine whether there may have been a difference between the
groups in rate of recurrence of either a second primary tumour or
distant metastases (data not shown).
None of these four trials reported on quality of life, or any measure
of patient satisfaction in the two groups.
Comparison 2: Radical neck dissection versus
selective neck dissection
The two trials (BHNCSG 1998; Bier 1994) in this comparison
compared neck dissection surgery of differing extent. There were
differences between the two studies with regard to patient charac-
teristics at baseline and surgical procedures so meta-analysis was
not undertaken.
BHNCSG 1998 compared a modified classical neck dissection
procedure with accessory nerve preservation, to a supraomohyoid
neck dissection (SOH) to achieve a compartmental excision of
levels I to III neck nodes in 148 patients with T2 to T4 primary
lesions in the oral cavity and clinically negative necks. Frozen sec-
tions were carried out on the nodes during surgery and 3 patients
in the SOH group who were found to have histologically positive
nodes then underwent the modified classical neck dissection in-
stead. This trial was at unclear risk of bias.
In Bier 1994 104 patients with either clinically negative or pos-
itive but movable, neck nodes were randomised to either radical
neck dissection or a selective neck dissection where the platysma,
the sternocleidomastoid muscle, the internal jugular vein and the
accessory nerve were left in place. Primary tumours were in the
oral cavity and the study was assessed at high risk of bias.
There is no evidence from these two trials of a difference in overall
survival, disease free survival or disease recurrence between the
radical or more selective neck dissection surgery (Analysis 2.1;
Analysis 2.2; Analysis 2.3).
The following adverse effects were reported in the BHNCSG
1998 trial: flap necrosis, wound infection, fistula, vascular rupture,
hematoma, seroma, chyle fistula. There were no complications in
45 patients (59%) in the modified radical neck dissection group
and none in 54 patients (75%) in the supraomohyoid neck dissec-
tion group. There were two postoperative deaths in the modified
radical neck dissection group and one in the supraomohyoid neck
dissection group.
Comparison 3: Radiotherapy plus surgery versus
radiotherapy alone
One trial compared surgery plus postoperative radiotherapy with
radiotherapy alone (Robertson 1998). Those in the surgery group
hadwide local excision of the primary tumour together with either
a radical neck dissection or a more selective neck dissection at the
discretion of the surgeon. It was planned to accrue 175 patients to
each arm of the trial but after 35 patients had been recruited the
trial was stopped due to the high death rate in the radiotherapy
alone arm. Data in Analysis 3.1 are from an interim analysis of
35 participants after 23 months and show a hazard ratio for total
mortality of 0.24 (95% confidence interval (CI) 0.10 to 0.59),
favouring the surgery group. This estimate should be interpreted
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with extreme caution for a number of reasons. The authors state
that “the difference in survival is likely to be inflated” due to the
small number of participants in the analysis, the fact that only 41%
of patients in the radiotherapy only arm received their radiotherapy
as planned due to problems with machine breakdown/servicing,
and that there were a number of other protocol violations in the
trial. In the surgery plus radiotherapy arm of this trial 50% of
the patients received their radiotherapy as planned, but 12% of
participants in this group received neither surgery to the mandible
nor neck dissection.
The following severe acute side effectswere reported in both groups
(Robertson 1998): subcutaneous fibrosis, telangiectasia (1 to 4
cm²), and moderate to severe oedema, xerostomia, trismus and
dysphagia. Subcutaneous fibrosiswas reported asmore prevalent in
the surgery plus radiotherapy group (P=0.042), but the prevalence
of other side effects appeared to be similar in each group.
D I S C U S S I O N
Summary of main results
This systematic review was undertaken to answer the question
’Does treatment with surgery improve the outcomes for patients
with oral cavity and oropharyngeal cancers?’. There were seven
randomised controlled trials (RCTs) included in this review with
a combined total of 669 patients randomised. All but two of these
patients had oral cavity cancers. None of the trials were at low risk
of bias.
None of the included trials compared different surgical approaches
to the removal of the primary tumour. Four of the included trials
evaluated the timing of neck dissection surgery in the course of
treatment and two included trials evaluated the extent of neck
dissection.
• Four trials compared elective neck dissection surgery
undertaken at the same time as excision of the primary tumour
with the option of excision of the primary alone, followed by
subsequent neck dissection surgery if and when neck nodes
showed clinical signs of cancer (therapeutic neck dissection). All
patients had oral cavity cancers, specifically tongue or floor of
mouth tumours, and clinically negative neck nodes. One trial
showed a difference in overall survival and disease free survival
after three and a half years of follow-up, favouring elective SOH
neck dissection compared to therapeutic neck dissection. In two
trials where the elective procedure was a radical neck dissection
there was no difference between the elective and therapeutic
groups with regard to either overall or disease free survival. The
fourth trial in this group did not report overall or disease free
survival. There is some evidence from that locoregional disease
recurrence is reduced following elective neck resection, but data
were unsuitable for meta-analysis.
• A further two trials, compared elective radical
(comprehensive) neck dissection with a selective neck dissection
in patients with oral cavity cancers. One trial included only
patients with clinically negative neck nodes and the other
included those with movable positive neck nodes as well. There
is no evidence from these two trials of a difference in overall
survival between the two types of surgery, and in the single trial
that reported disease free survival and disease recurrence there
was no difference between the two types of surgery.
• The third comparison was between surgery plus
postoperative radiotherapy and radiotherapy alone but the only
trial in this comparison was stopped early due to an unacceptably
high death rate in the radiotherapy alone group. There was a
difference in overall survival favouring the surgery plus
radiotherapy group. These results should be interpreted with
caution because the nature of the interim analysis on 35 patients
(10% of planned recruitment) may inflate the difference between
the groups. Also there were a number of protocol violations
(more than half of the participants did not receive their
radiotherapy as planned due to machine breakdown/servicing)
which may partially explain the poor outcome in the
radiotherapy alone group.
While there is weak evidence from these included trials that early
or extensive dissection of the lymph nodes in the clinically negative
neck reduces locoregional recurrence, there is no strong evidence
of a difference in overall survival, or disease free survival. There is
no information from these trials on quality of life of the patients
who have undergone the different neck dissection procedures.
Overall completeness and applicability of
evidence
This review originally sought to evaluate the benefits of all surgi-
cal treatment modalities used alone or in conjunction with other
treatment regimens such as radiotherapy, chemotherapy and ra-
diotherapy. However, this led to multiple treatment comparisons
of studies that did not necessarily differ purely on the surgical
treatment method. This review is one of a series of reviews in oral
cancer looking at surgery, radiotherapy, chemotherapy and im-
munotherapy. Therefore for this update, the protocol for this re-
view was modified to only include studies where different surgical
treatment modalities were directly compared against one another,
or surgery was compared to a different treatment regimen such
as radiotherapy, chemotherapy or immunotherapy. All other stud-
ies were removed from the updated review, and where appropri-
ate were incorporated into the other oral cancer reviews (Furness
2011; Glenny 2010).
The inclusion criteria for this review specified that trials of surgery
where participants had either oral cavity or oropharyngeal cancer
would be included. However for this update of the review only
seven trials were identified and 667 of the total of 669 participants
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in these trials had oral cavity cancers, most commonly in either
the tongue or floor of mouth. The trials, each including between
35 and 167 participants, recruited patients over four decades be-
tween 1966 and 2004. There have been significant developments
in both the surgical and adjuvant treatments for oral cavity cancer
patients over the past decade and these are incompletely evaluated
in this systematic review due to the lack of randomised controlled
trials in this condition. It is encouraging to note that there are cur-
rently three large trials ongoing (NCT00193765;NCT01334320;
NCT00571883 (SEND)) which will provide further information
concerning the benefits and harms of different surgical options for
neck dissection in oral cavity cancer patients.
Only two of the included studies reported harms or adverse events
to treatment (BHNCSG 1998; Robertson 1998) but neither pre-
sented outcomes per person. Aggressive surgery to remove the can-
cer and reduce the risk of recurrence has been associated with very
significant adverse effects on both appearance and functions such
as breathing, speech and swallowing. Less aggressive surgery, such
as selective lymph node dissection is associated with a greater risk
of recurrence, but preservation of function and appearance. In-
corporation of quality of life outcomes into randomised trials is
essential if the true benefits and harms of different types of surgery
are to be evaluated. It is noteworthy that while some of the trials
included in this review reported that some patients, randomly al-
located to surgery, refused surgical treatment and were withdrawn
from the trials, there is no report of the quality of life of these
patients compared to those included in the trials.
We did not identify any trials of surgery in patients with oropha-
ryngeal cancer, probably because the current therapeutic approach
to oropharyngeal cancer is either radiotherapy or chemoradiother-
apy. Over the past decade the percentage of patients with oropha-
ryngeal cancer who test positive for human papilloma virus (HPV)
has increased steadily. It is now recognised that HPV status of pa-
tients with oropharyngeal cancer is an important factor in their
prognosis (Adelstein 2009; Brizel 2011).
Quality of the evidence
The overall quality of the evidence included in this systematic re-
view is poor. All of the included trials were at either high or unclear
risk of bias. Patients were recruited over 4 decades. For objective
outcomes such as total mortality, trials assessed as adequate with
regard to the domains of sequence generation, allocation conceal-
ment, complete outcome data and absence of selective reporting,
were planned to be assessed as being at low risk of bias. None of
the included studies met all these criteria. None of the trials in-
cluded in this systematic review used, or reported using, blinding
of either the participants or the outcome assessors. It is recognised
that blinding is difficult to maintain in trials of surgery and it may
not be either possible or indeed ethical, to blind trial participants.
It is likely that many outcome assessments are performed by the
clinicians treating the patients.
There has been substantial development in the surgical and non-
surgical treatments for both oral and oropharyngeal cancers over
recent years. Further objective assessments of current surgical treat-
ments for these cancers are needed in order to inform both patients
and clinicians about the benefits and risks of different treatments.
Potential biases in the review process
The search strategy employed was comprehensive with no lan-
guage restrictions, and inclusion criteria for the review were clearly
specified in line with the other reviews in this series (Furness 2011;
Glenny 2010) so the risk of biased selection of studies was mini-
mal.
Agreements and disagreements with other
studies or reviews
Two reviews of treatment of neck dissection in the surgical treat-
ment of oral cavity cancer have been published based on the same
included studies (Fasunla 2011; Kowalski 2007). Kowalski 2007
looked at dichotomous outcomes (percentages in each group) in
three RCTs. No meta-analysis was undertaken and only the sum-
mary outcome estimates were noted, without regard to the vari-
ance of these. Their conclusions are based on “vote-counting”.
Fasunla 2011 reviewed four RCTs and reported the dichotomous
outcome of disease-specific death after approximately 3 years of
follow-up. This review found that the risk ratio (RR) of disease
specific death favoured elective neck dissection (RR 0.57; 95%
confidence interval (CI) 0.36 to 0.89).
We have chosen to use the outcome of overall survival/total mor-
tality because we believe this is the more important outcome for
patients, and we have used hazard ratios where possible, as they
have the advantage of incorporating all available information, in-
cluding data from patients who fail to complete the trial, in the
outcome. We look forward to the addition of data from the three
ongoing trials identified to the next update of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The trials included in this review do not address different surgical
approaches to removal of the primary tumour. From the four tri-
als of patients with oral cavity cancers there is no strong evidence
that elective dissection of clinically negative neck nodes compared
to therapeutic neck dissection results in better or worse overall
survival or disease free survival. From two trials there is no evi-
dence that radical neck dissection results in better or worse overall
survival or disease free survival compared to selective neck dissec-
tion. However elective neck dissection does reduce locoregional
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recurrence. More information about the effects of these surgeries
on patients’ quality of life is required in order to fully assess the
benefits and harms of these surgical procedures.
Implications for research
We would make the following recommendations for future re-
search involving the surgical treatment of oral or oropharyngeal
tumours.
(1) Trialists are encouraged to follow the CONSORT guidelines
when reporting on their trials. Ideally trials should report hazard
ratios with 95% confidence intervals for survival data, or present
data that allows for the calculation of this estimate of effect.
(2) Health-related quality of life is an important outcome measure
that should be integral to all trials of oral cavity and oropharyngeal
cancers.
(3) There should be a standardised and consistent reporting of ad-
verse events and morbidity associated with treatment, with results
reported per patient.
(4) Future trials of oral cavity and oropharyngeal cancers should
report data based on the location of the primary tumour.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
BHNCSG 1998
Methods Location of trial: Brazil
Number of centres: Multicentre (8)
Funding: Not stated
Trial ID: Not stated
Participants Inclusion criteria: Resectable T2 to T4 lesions, clinically negative neck (N0), no prior
treatment, histologic diagnosis of squamous cell carcinoma of the oral tongue, floor of
the mouth, inferior gingiva, or retromolar trigone, no need for myocutaneous or free
flaps for reconstruction, and a Karnofsky’s score of 60 or greater
Exclusion criteria: Significant cardiac or pulmonary diseases, distant metastases and/or
multiple primary cancers
Recruitment period: May 1990 to December 1993
Number randomised: 148 (all OC - 42% tongue, 33% FOM, 8% inferior gingiva, 17%
retromolar trigone)
Number analysed: 148
Interventions Modified radical classical neck dissection (MRND) versus supraomohyoid neck
dissection (SOH)
Gr 1 (n = 76): MRND - surgery conducted centripetally toward the submandibular
triangle
Gr 2 (n = 72): SOH - dissection performed to achieve a compartmental excision of levels
I, II and III lymph nodes. Where a positive node was confirmed during the procedure
the operation was converted to a MRND
For both groups, postoperative radiotherapy was indicated in cases with positive margins
and/or positive lymph nodes in the specimen. Radiotherapywas over 5 consecutive weeks
to deliver a total dose of 50 Gy
All patients had primary tumour resection.
Outcomes Primary: Overall survival
Secondary: Recurrence, length of hospital stay, adverse events
Duration of follow-up: 5 years
Notes HR data taken from Kaplan-Meier graph (no numbers at risk).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were stratified by institution and
laterality (unilateral or bilateral) and subse-
quently randomised”. Method of sequence
generation not described
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BHNCSG 1998 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no’.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blind outcome assessment not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk Groups appeared similar at baseline.No ev-
idence of other potential sources of bias
Bier 1994
Methods Location of trial: Germany, Austria and Switzerland
Number of centres: Multicentre
Funding: Not stated
Trial ID: Not stated (part of The German-Austrian-Swiss Association for Head and Neck
Tumours (DOSAK))
Participants Inclusion criteria: Untreated SCC of the oral cavity without metastases, primary tumour
on one side postcanine or postmolar, i.e. second or third part of the tongue, respectively,
nonpalpable or clinically negative, or clinically positive, movable lymph nodes in the
neck
Exclusion criteria: Fixed lymph nodes in the neck.
Recruitment period: Uncertain
Number randomised: 167 (allOC - 37%tongue, 21%FOM,16%RMT, 14%mandible,
8% maxilla, 3% cheek, 1% other)
Number analysed: 104
Interventions Radical neck dissection versus selective neck dissection
Gr 1 (n = 48): Radical neck dissection (ipsilateral) on the draining lymph nodes. Radical
dissection designated as removal of: i) platysma, sternocleidomastoid muscle, omohyoid
muscle, stylohyoid muscle, the distal part of the biventer cervicis and the fascia colli; ii)
the accessory nerve, the descending branch of the hypoglossus nerve, the branches of the
cervical plexus; iii) the cervical vein, the superficial jugular vein and the internal jugular
vein; iv) fat tissue, the submandibular gland and the lower part of the parotid gland
Gr 2 (n=56): Selective neck dissection (ipsilateral) on the draining lymphnodes. Selective
dissection designated as retention of the platysma, sternocleidomastoid muscle, internal
jugular vein and the accessory nerve
All patients underwent radical resection of the primary tumour
Outcomes Primary: Overall survival
Secondary: Recurrence, metastases
Duration of follow-up: 4 years
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Bier 1994 (Continued)
Notes Preliminary report.
Neck dissection was followed by radiotherapy and/or chemotherapy in patients not
undergoing radical resection of the primary tumour and in patients with capsular rupture
in at least one lymph node. These patients were not included in the analysis
HR data taken from Kaplan-Meier graph (no numbers at risk).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized according to the treatment-
dependant prognostic index (TPI) of the
DOSAK”. Method of sequence generation
not described
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no’.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blind outcome assessment not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk Interim analysis of 104/167 patients ran-
domised published in 1994.No subsequent
publication identified. Patients who did
not have radical surgery at the primary site
and those who had extracapsular rupture of
at least one lymph node are not included
in the evaluation
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Unclear risk No information about comparability of
groups at baseline.
Fakih 1989
Methods Location of trial: India
Number of centres: 1
Funding: Not stated
Trial ID: Not stated
Participants Inclusion criteria: T1 to T2, N0 M0, histologically proven SCC of the anterior two
thirds of the oral tongue
Exclusion criteria: Not stated.
Recruitment period: July 1985 to September 1988
Number randomised: 100 (all OC -100% tongue)
Number analysed: 70
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Fakih 1989 (Continued)
Interventions Elective radical neck dissection versus therapeutic radical neck dissection
Gr 1 (n = 30): Radical neck dissection (ipsilateral).
Gr 2 (n = 40): Only those developing neck node metastasis underwent radical neck
dissection
All patients underwent resection of the primary tumour (standard anterior two-thirds
hemiglossectomy)
Outcomes Primary: Disease free survival
Secondary: Overall survival, disease related mortality, recurrent disease
Duration of follow-up: 1 year
Notes No data available for calculation of HR.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomised from previously generated
random numbers”.
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no’.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blind outcome assessment not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk Interim analysis, no final analysis reported.
73 participants entered into protocol, 12
refused treatment and 2 were declared un-
fit for surgery. Of the remaining 59 who
completed initial treatment, 35 who com-
pleted a median of 22 months follow-up
are included in the analysis (approximately
48%)
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Unclear risk No information about comparability of
groups at baseline.
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Kligerman 1994
Methods Location of trial: Brazil
Number of centres: 1
Funding: Government (personal communication)
Trial ID: Not stated
Participants Inclusion criteria: Resectable early stage (T1 to T2, N0) SCC of tongue and floor of
mouth
Exclusion criteria: Not stated.
Recruitment period: 1987 to 1992
Number randomised: 67 (all OC - 61% tongue, 39% FOM)
Number analysed: 67
Interventions Elective neck dissection versus therapeutic neck dissection
Gr 1 (n = 34): Elective supraomohyoid neck dissection. Dissection of levels 1 to 3 plus
resection of submandibular gland, preserving the sternocleidomastoid muscle, spinal
accessory nerve and internal jugular vein.
Gr 2 (n = 33): Therapeutic neck dissection.
All patients underwent resection of the primary tumour.
Outcomes Primary: Total mortality
Secondary: Disease free survival, locoregional failures, recurrent disease, disease related
mortality
Duration of follow-up: 3.5 years
Notes Paper reports that overall survival assessed by Kaplan-Meier actuarial method, but not
presented
HR data taken from Kaplan-Meier graph (no numbers at risk) for DFS
Locoregional failure data unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All 67 patients were stratified by stage ...
and those in each stage were randomised”.
Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no’.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blind outcome assessment not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs.
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Kligerman 1994 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Unclear risk No information about comparability of
groups at baseline.
Robertson 1998
Methods Location of trial: UK
Number of centres: Multicentre (4)
Funding: Not stated
Trial ID: Not stated
Participants Inclusion criteria: Resectable, stage T2 to T4, N0 to N2, M0 H&N tumours
Exclusion criteria: Stage I (T1N0M0), history of previous malignancy, apart from basal
cell carcinoma of the skin, or intraepithelial carcinoma of the cervix
Recruitment period: December 1991 to December 1993
Number randomised: 35 (intended 350 but trial stopped early due to concern of the
number of deaths in the radiotherapy alone arm) (33/35 OC - 40% tongue, 43% FOM,
11% RMT, 6% tonsil)
Number analysed: 35
Interventions Surgery plus radiotherapy versus radiotherapy alone
Gr 1 (n = 17): Radical resection and neck dissection plus postoperative radiotherapy.
Radical surgery involvedwide local excision of the primary tumourwith a 1 cmmargin. A
radical or functional neck dissection was carried out at the same time at the discretion of
the surgeon. Reconstruction of the oral cavity was carried out immediately. Postoperative
radiotherapy comprised 60 Gy in 30 fractions over 6 weeks, commencing within 6 to 8
weeks of surgery.
Gr 2 (n = 18): Radiotherapy alone 66 Gy in 33 fractions over 6.5 weeks, receiving 2 Gy
per day
Outcomes Primary: Locoregional control
Secondary: Overall survival, disease free interval, recurrent disease, adverse events
Duration of follow-up: 3 years
Notes HR data taken from Kaplan-Meier graph (no numbers at risk).
Data presented in Kaplan-Meier estimates for disease free survival, but not used as graph
starts at 50% for XTR alone arm.
Authors provided additional information relating to allocation concealment and the
characteristics of tumours
Risk of bias
Bias Authors’ judgement Support for judgement
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Robertson 1998 (Continued)
Random sequence generation (selection
bias)
Low risk “Random permuted blocks of four were
used for randomization” following stratifi-
cation according to institution and site of
primary disease
Allocation concealment (selection bias) Low risk Randomisation via a telephone call to the
West of Scotland Clinical Trials Office
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blind outcome assessment not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs.
Selective reporting (reporting bias) Low risk No evidence of selective reporting of out-
comes.
Other bias High risk Anticipated enrolment of 350 patients, but
trial stopped after 35 patients recruited be-
cause clinicians felt it was unethical to con-
tinue. Appropriate procedures and analysis
were conducted. More than half of those
recruited had either delays or interruptions
to the planned radiotherapy schedule. It is
likely that this would have had a greater ef-
fect on the outcomes of the radiotherapy
alone arm of this trial
Vandenbrouck 1980
Methods Location of trial: France
Number of centres: One
Funding: Not stated
Trial ID: Not stated
Participants Inclusion criteria: T1 to T3, N0, SCC oral cavity, tongue or lower floor of mouth.
Patients were any age or sex with no previous transcutaneous radiotherapy or interatrial
chemo infusion. Neck free of disease or with moveable submaxillary node/s no larger
than 1 cm
Exclusion criteria: Not stated.
Recruitment period: 1966 to 1973
Numbers randomised: 80 (all OC - 56% tongue, 44% FOM)
Numbers analysed: 75
Interventions Elective radical neck dissection versus therapeutic radical neck dissection
Gr 1 (n = 39): Elective neck dissection within 2 months of treatment of primary lesion.
In cases of lateral tumour an ipsilateral radical neck dissection with removal of stern-
ocleidomastoid muscle, internal jugular vein without sparing the spinal accessory nerve
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Vandenbrouck 1980 (Continued)
was performed. When tumour crossed or close to midline submental, submaxillary and
jugulodigastric contralateral dissection performed. Nodal involvement resulted in post-
operative radiotherapy.
Gr 2 (n = 36): Delayed therapeutic dissection. These patients were followed for at least
3 years and underwent neck dissection if a cervical node became enlarged
All patients received interstitial radiotherapy to the primary tumour site prior to ran-
domisation
Outcomes Primary: Overall survival
Secondary: Disease free survival, disease related mortality, other mortality, recurrent
disease
Duration of follow-up period: 5 years
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomisation was under the control of a
statistician who observed the strictest pro-
tocol”. However, method of sequence gen-
eration was not described
Allocation concealment (selection bias) Low risk “Randomisation was under the control of a
statistician who observed the strictest pro-
tocol”. Assumed that this was adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blind outcome assessment not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs.
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No evidence of other potential sources of
bias.
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Yuen 2009
Methods Location of trial: Hong Kong, China
Number of centres: 3
Funding: Not stated
Trial ID: Not stated
Participants Inclusion criteria: AJCC, St I to II, SCC oral tongue. No nodal metastases, no prior
surgery, chemotherapy of radiotherapy
Exclusion criteria: Oral cancer of other sub sites, or cancer of base of tongue
Recruitment period: 1996 to 2004
Numbers randomised: 72 (all OC - 100% tongue)
Numbers analysed: 71
Interventions Elective selective neck dissection versus therapeutic radical neck dissection
Gr 1 (n = 36): Elective ipsilateral selective neck dissection of level I, II, or III neck nodes.
Gr 2 (n = 36): Delayed therapeutic dissection. These patients were followed, and received
ultrasound examinations every 3 months for the first 3 years. If nodal recurrence was
detected these patients underwent either radical or modified radical neck dissection
followed by radiotherapy
All patients in the trial had transoral glossectomy with 1.5 resection margins
Outcomes Nodal recurrence, disease recurrence, death due to tumour, 5 year tumour specific survival
Notes Duration of follow-up: 34 to 122 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation stratified by tumour stage.
Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Used sealed envelopes to contain the alloca-
tion. Insufficient information to determine
whether allocation was concealed from in-
vestigators
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 patient allocated to observation group
was subsequently found to have T3 tumour
and was withdrawn. All other randomised
participants included in the outcome eval-
uations
Selective reporting (reporting bias) High risk Reported nodal and local recurrence, dis-
ease free survival and disease specific death.
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Yuen 2009 (Continued)
No reporting of mortality in each group
Other bias Low risk Groups appeared similar at baseline.
Gr = group; H&N = head and neck; OC/OP = oral cancer/oropharyngeal cancer; PORT = postoperative radiotherapy; RT = radio-
therapy; SCC = squamous cell carcinoma; SE = standard error;
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ang 2001 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy’
Bernier 2004 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Bier 1981 RCT to be included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: im-
munotherapy’
Cooper 2004 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
De Stefani 2002 RCT to be included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: im-
munotherapy’
Hintz 1979 H&N cancer study with < 50% oral cancer/oropharyngeal cancer
Hintz 1979a H&N cancer study with < 50% oral cancer/oropharyngeal cancer
Kramer 1987 Insufficient detail in published report to establish what the surgical procedures involved and whether these were
the same in all groups. Insufficient information to enable either risk of bias assessment to be undertaken
Lam 2001 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Laramore 1992 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Lawrence 1974 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy’
Licitra 2003 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
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(Continued)
Luboinski 1985 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Maipang 1995 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Mohr 1994 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Neifield 1985 RCT to be included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: im-
munotherapy’
Paccagnella 1994 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Rao 1991 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Rentschler 1987 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Richard 1991 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Sanguinetti 2005 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy’
Schuller 1988 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Szabo 1999 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Szpirglas 1978 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Terz 1981 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy’
Volling 1999 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
Weissler 1992 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’
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H&N = head and neck; IPD = individual patient data; OC = oral cancer; OP = oropharyngeal cancer; RCT = randomised controlled
trial; SCC = squamous cell carcinoma.
Characteristics of ongoing studies [ordered by study ID]
NCT00193765
Trial name or title Elective versus therapeutic neck dissection in the treatment of early node negative squamous carcinoma of
the oral cavity (NCT00193765)
Methods RCT.
Participants histologically proven T1 to T2, N0M0, SCC of buccal mucosa, lower alveolus, oral tongue or floor of mouth
Interventions Elective neck dissection versus therapeutic neck dissection.
Outcomes Survival (5 years), role of ultrasound in diagnosis and follow-up, accuracy of surgeon assessment of tumour
thickness, identification of histological prognostic factors
Starting date January 2004. Planned enrolment 710.
Contact information Dr Anil D’cruz, Tata Memorial Hospital, Mumbai, India (adcruz@vsnl.com)
Notes Currently recruiting March 2010.
NCT00571883 (SEND)
Trial name or title Neck surgery in treating patients with early-stage oral cancer (SEND trial) (NCT00571883)
Methods RCT.
Participants Patients with oral squamous cell carcinoma 1 to 3 cm at primary site, no clinical or preoperative imaging
evidence of neck involvement (N0)
Interventions Selective elective neck dissection plus resection of primary tumour versus resection of primary alone
Outcomes Overall survival, disease free survival, local and regional recurrence, completeness of primary resection, quality
of life, psychological well being, costs
Starting date January 2007.
Contact information Study chair: Iain Hutchison, Facial Surgery Research Foundation, UK (send@savingfaces.info)
Notes Currently recruiting July 2009.
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NCT01334320
Trial name or title Survival benefit of elective neck dissection in T1, 2 N0 M0 oral squamous cell carcinoma (NCT01334320)
Methods RCT.
Participants Histologically proven T1 or T2 N0 M0 (clinical) squamous cell carcinoma of oral tongue, buccal mucosa,
gingiva, floor of mouth or hard palate
Interventions Elective superior omohyoid neck dissection versus watch and wait (resection of primary tumour and thera-
peutic dissection of neck when clinical evidence of disease)
Outcomes Overall and disease free survival at 5 years, recurrence, quality of life
Starting date April 2011. Planned enrolment 448.
Contact information Dr Guiqing Lao, Hospital of Stomatology, Sun Yat-sen University, Guangdong, China (drliaogu-
iqing@hotmail.com)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Elective neck dissection versus therapeutic (delayed) neck dissection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Elective radical neck
dissection versus therapeutic
neck dissection (1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Elective SOH neck
dissection vs therapeutic neck
dissection (3.5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Total mortality 1 Hazard Ratio (Fixed, 95% CI) Totals not selected
2.1 Elective radical neck
dissection versus therapeutic
radical neck
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Disease-free survival 1 Hazard Ratio (Fixed, 95% CI) Totals not selected
3.1 Elective SOH neck
dissection vs therapeutic neck
dissection (3.5 years)
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Disease-free survival 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Elective radical neck
dissection versus therapeutic
neck dissection (1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Elective radical neck
dissection versus therapeutic
radical neck dissection (3 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Locoregional recurrence 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Elective radical neck
dissection versus therapeutic
neck dissection (1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Elective SOH neck
dissection versus therapeutic
neck dissection (3.5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Elective selective neck
dissection vs therapeutic neck
dissection
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Elective radical neck
dissection versus therapeutic
radical neck dissection (3 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Radical neck dissection versus selective neck dissection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 2 Hazard Ratio (Fixed, 95% CI) Totals not selected
1.1 Modified radical classical
neck dissection (MRND) vs
supraomohyoid neck dissection
(SOH)
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Radical neck dissection
versus selective neck dissection
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Disease-free survival 1 Hazard Ratio (Fixed, 95% CI) Totals not selected
2.1 Radical neck dissection
versus selective neck dissection
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Disease Recurrence 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Resection plus elective
supraomohyoid dissection
versus resection alone (5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Surgery plus radiotherapy versus radiotherapy alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 1 Hazard Ratio (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Elective neck dissection versus therapeutic (delayed) neck dissection, Outcome
1 Total mortality.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection versus therapeutic (delayed) neck dissection
Outcome: 1 Total mortality
Study or subgroup Elective ND Therapeutic ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective radical neck dissection versus therapeutic neck dissection (1 year)
Fakih 1989 9/28 16/37 0.74 [ 0.39, 1.43 ]
2 Elective SOH neck dissection vs therapeutic neck dissection (3.5 years)
Kligerman 1994 7/34 17/33 0.40 [ 0.19, 0.84 ]
0.1 0.2 0.5 1 2 5 10
Favours Elective ND Favours Therapeutic ND
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Analysis 1.2. Comparison 1 Elective neck dissection versus therapeutic (delayed) neck dissection, Outcome
2 Total mortality.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection versus therapeutic (delayed) neck dissection
Outcome: 2 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Elective radical neck dissection versus therapeutic radical neck
Vandenbrouck 1980 0.3 (0.42) 1.35 [ 0.59, 3.07 ]
0.01 0.1 1 10 100
Favours Elective ND Favours Therapeutic ND
Analysis 1.3. Comparison 1 Elective neck dissection versus therapeutic (delayed) neck dissection, Outcome
3 Disease-free survival.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection versus therapeutic (delayed) neck dissection
Outcome: 3 Disease-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Elective SOH neck dissection vs therapeutic neck dissection (3.5 years)
Kligerman 1994 -1.15 (0.5) 0.32 [ 0.12, 0.84 ]
0.01 0.1 1 10 100
Favours Elective ND Favours Therapeutic ND
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Analysis 1.4. Comparison 1 Elective neck dissection versus therapeutic (delayed) neck dissection, Outcome
4 Disease-free survival.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection versus therapeutic (delayed) neck dissection
Outcome: 4 Disease-free survival
Study or subgroup Elective ND Therapeutic ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective radical neck dissection versus therapeutic neck dissection (1 year)
Fakih 1989 19/28 21/37 1.20 [ 0.82, 1.75 ]
2 Elective radical neck dissection versus therapeutic radical neck dissection (3 years)
Vandenbrouck 1980 18/39 21/36 0.79 [ 0.51, 1.23 ]
0.1 0.2 0.5 1 2 5 10
Favours Elective ND Favours Therapeutic ND
Analysis 1.5. Comparison 1 Elective neck dissection versus therapeutic (delayed) neck dissection, Outcome
5 Locoregional recurrence.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection versus therapeutic (delayed) neck dissection
Outcome: 5 Locoregional recurrence
Study or subgroup Elective ND Therapeutic ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective radical neck dissection versus therapeutic neck dissection (1 year)
Fakih 1989 11/28 23/37 0.63 [ 0.37, 1.07 ]
2 Elective SOH neck dissection versus therapeutic neck dissection (3.5 years)
Kligerman 1994 8/34 14/33 0.55 [ 0.27, 1.14 ]
3 Elective selective neck dissection vs therapeutic neck dissection
Yuen 2009 6/36 14/35 0.42 [ 0.18, 0.96 ]
4 Elective radical neck dissection versus therapeutic radical neck dissection (3 years)
Vandenbrouck 1980 6/39 8/36 0.69 [ 0.27, 1.80 ]
0.1 0.2 0.5 1 2 5 10
Favours Elective ND Favours Therapeutic ND
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Analysis 2.1. Comparison 2 Radical neck dissection versus selective neck dissection, Outcome 1 Total
mortality.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 2 Radical neck dissection versus selective neck dissection
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Modified radical classical neck dissection (MRND) vs supraomohyoid neck dissection (SOH)
BHNCSG 1998 0.13 (0.25) 1.14 [ 0.70, 1.86 ]
2 Radical neck dissection versus selective neck dissection
Bier 1994 -0.14 (0.38) 0.87 [ 0.41, 1.83 ]
0.01 0.1 1 10 100
Comprehensive ND Selective ND
Analysis 2.2. Comparison 2 Radical neck dissection versus selective neck dissection, Outcome 2 Disease-
free survival.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 2 Radical neck dissection versus selective neck dissection
Outcome: 2 Disease-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Radical neck dissection versus selective neck dissection
Bier 1994 -0.56 (0.34) 0.57 [ 0.29, 1.11 ]
0.01 0.1 1 10 100
Comprehensive ND Selective ND
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Analysis 2.3. Comparison 2 Radical neck dissection versus selective neck dissection, Outcome 3 Disease
Recurrence.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 2 Radical neck dissection versus selective neck dissection
Outcome: 3 Disease Recurrence
Study or subgroup Radical ND Selective ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Resection plus elective supraomohyoid dissection versus resection alone (5 years)
BHNCSG 1998 16/72 13/71 1.21 [ 0.63, 2.33 ]
0.1 0.2 0.5 1 2 5 10
Comprehensive ND Selective ND
Analysis 3.1. Comparison 3 Surgery plus radiotherapy versus radiotherapy alone, Outcome 1 Total
mortality.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 3 Surgery plus radiotherapy versus radiotherapy alone
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Robertson 1998 -1.427 (0.456) 0.24 [ 0.10, 0.59 ]
0.01 0.1 1 10 100
Favours surgery + RT Favours RT alone
A D D I T I O N A L T A B L E S
Table 1. Stage of cancer
Study
BHNCSG 1998 T2 to T4 Negative neck
Bier 1994 ns Negative or positive neck
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Table 1. Stage of cancer (Continued)
Fakih 1989 T1 or T2 Negative neck
Kligerman 1994 T1 or T2 Negative neck
Robertson 1998 T2 to T4 Negative or positive neck
Vandenbrouck 1980 T1 to T3 Negative neck
A P P E N D I C E S
Appendix 1. MEDLINE (OVID) Search Strategy
1. “Head and Neck Neoplasms”/
2. “Mouth Neoplasms”/
3. “Gingival Neoplasms”/
4. “Palatal Neoplasms”/
5. “Tongue Neoplasms”/
6. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or
carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or intraoral$ or
“intra oral$” or gingiva$or oropharyn$ ormouth$or tongue$ or cheek$or gum$or palatal$ or palate$ or “head andneck”)).mp.
7. or/1-6
8. exp Radiotherapy/
9. (radiotherap$ or chemotherap$ or chemoradiotherap$ or chemo-
radiotherap$ or “radiation therap$” or bracytherap$ or irradiat$).ti,ab.
10. (adjuvant or neo-adjuvant or “neo adjuvant”).ti,ab.
11. (hyperfractionate$ or hyper-fractionate$).mp.
12. exp Surgical Procedures, Operative/
13. (dissect$ adj2 neck$).ti,ab.
14. (excision or excise or resect$).ti,ab.
15. Lymph Node Excision/
16. (lymphadenectom$ or glossectom$).ti,ab.
17. exp Antineoplastic agents/
18. (antineoplast$ or antitumor$ or anti-tumor$ or anti-neoplast$).mp.
19. Antineoplastic combined chemotherapy protocols/
20. exp Combined Modality Therapy/
21. or/8-20
22. 7 and 21
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009] (Higgins 2009)
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
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5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 2. Cochrane Oral Health Group Trials Register Search Strategy
((mouth or oral or intraoral or intra-oral or gingiva* or oropharyn* or cheek* or gum* or palat* or lip or tongue or “head and neck”)
AND (tumour* or tumor* or cancer* or carcinoma* or neoplas* or malignan*))
Appendix 3. Cochrane Central Register of Controlled Trials (CENTRAL) Search Strategy
#1 MeSH descriptor Head and neck neoplasms this term only
#2 MeSH descriptor Mouth Neoplasms this term only
#3 MeSH descriptor Gingival Neoplasms this term only
#4 MeSH descriptor Palatal Neoplasms this term only
#5 MeSH descriptor Tongue Neoplasms this term only
#6 ( (cancer* in All Text or tumour* in All Text or tumor* in All Text or
neoplas* in All Text or malignan* in All Text or carcinoma* in All Text or metatasta* in All Text) and (oral* in All Text or intra-oral*
in All Text or intraoral* in All Text or “intra oral*” in All Text or gingiva* in All Text or oropharyn* in All Text or mouth* in All Text
or tongue* in All Text or cheek* in All Text or gum* in All Text or palatal* in All Text or palate* in All Text or “head and neck” in All
Text) )
#7 (#1 or #2 or #3 or #4 or #5 or #6)
#8 MeSH descriptor Radiotherapy explode all trees
#9 (radiotherap* in Title, Abstract or Keywords or chemotherap* in Title,
Abstract or Keywords or chemoradiotherap* in Title, Abstract or Keywords or chemo-radiotherap* in Title, Abstract or Keywords or
“radiation therap*” in Title, Abstract or Keywords or bracytherap* in Title, Abstract or Keywords or irradiat* in Title, Abstract or
Keywords)
#10 (adjuvant in Title, Abstract or Keywords or neo-adjuvant in Title, Abstract or
Keywords or “neo adjuvant” in Title, Abstract or Keywords)
#11 (hyperfractionate* in All Text or hyper-fractionate* in All Text)
#12 MeSH descriptor Surgical procedures, operative explode all trees
#13 (dissect* in Title, Abstract or Keywords near/2 neck* in Title, Abstract or
Keywords)
#14 MeSH descriptor Lymph Node Excision this term only
#15 (lymphadenectom* in Title, Abstract or Keywords or glossectom* in Title,
Abstract or Keywords)
#16 MeSH descriptor Antineoplastic agents explode all trees
#17 (antineoplast* in All Text or antitumor* in All Text or anti-tumor* in All Text
or anti-neoplast* in All Text)
#18 (excision in Title, Abstract or Keywords or excise in Title, Abstract or
Keywords or resect* in Title, Abstract or Keywords)
#19 MeSH descriptor Antineoplastic combined chemotherapy protocols this term
only
#20 MeSH descriptor Combined Modality Therapy explode all trees
#21 (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or
#19 or #20)
#22 (#7 and #21)
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Appendix 4. EMBASE (OVID) Search Strategy
1. “Head and Neck Neoplasms”/
2. “Mouth Neoplasms”/
3. “Gingival Neoplasms”/
4. “Palatal Neoplasms”/
5. “Tongue Neoplasms”/
6. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or
carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or intraoral$ or
“intra oral$” or gingiva$or oropharyn$ ormouth$or tongue$ or cheek$or gum$or palatal$ or palate$ or “head andneck”)).mp.
7. or/1-6
8. exp Radiotherapy/
9. (radiotherap$ or chemotherap$ or chemoradiotherap$ or chemo-
radiotherap$ or “radiation therap$” or bracytherap$ or irradiat$).ti,ab. 10. (adjuvant or neo-adjuvant or “neo adju-
vant”).ti,ab.
11. (hyperfractionate$ or hyper-fractionate$).mp.
12. exp Surgical Procedures, Operative/
13. (dissect$ adj2 neck$).ti,ab.
14. (excision or excise or resect$).ti,ab.
15. Lymph Node Excision/
16. (lymphadenectom$ or glossectom$).ti,ab.
17. exp Antineoplastic agents/
18. (antineoplast$ or antitumor$ or anti-tumor$ or anti-neoplast$).mp.
19. Antineoplastic combined chemotherapy protocols/
20. exp Combined Modality Therapy/
21. or/8-20
22. 7 and 21
The above subject search was linked to the Cochrane Oral Health Group filter for EMBASE via OVID:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
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WH A T ’ S N E W
Last assessed as up-to-date: 16 February 2011.
Date Event Description
4 July 2011 New citation required and conclusions have changed Two new trials added. New comparisons, and conclusions.
Twenty-four previously included trials now moved to other
oral cancer reviews on chemotherapy and radiotherapy
4 July 2011 New search has been performed Searches updated to 17 February 2011.
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 4, 2007
Date Event Description
28 April 2009 Amended Minor changes to the data.
20 June 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
• Richard Oliver (RO), Jan Clarkson (JC), Helen Worthington (HW) and Anne-Marie Glenny (AMG) conceived, designed and
sought funding for the review.
• Alyson Bessell (AB) co-ordinated and managed the review update.
• The trials search strategy was refined with input from Anne Littlewood (AL), AMG & Susan Furness (SF).
• SF, AMG and AB screened the titles and abstracts.
• SF organised retrieval of papers.
• AB, AMG and SF screened retrieved papers against the inclusion criteria.
• AB, SF, HW and AMG appraised the quality of the papers, and extracted data.
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• Sue Pavitt (SP) obtained additional data on published studies; these were then analysed by HW, SP and AMG in the original
review.
• HW, AMG and SP provided a methodological perspective.
• David Conway (DC), RO, Michaelina Maclusky (MM), and Philip Sloan (PS) provided a clinical perspective.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• School of Dentistry, The University of Manchester, UK.
• Cochrane Oral Health Group, UK.
• The University of Dundee, UK.
• The University of Glasgow, UK.
External sources
• National Institute of Health, National Institute of Dental & Craniofacial Research, USA.
• Central Manchester & Manchester Children’s University Hospitals NHS Trust, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Types of interventions: The intervention under evaluation must be surgery. Trials where all participants receive the same surgical
regimen and are randomised to other treatments were excluded.
Search methods: The search strategy has been updated.
Quality assessment has been replaced by the new risk of bias tool (Higgins 2011).
Data synthesis has been updated. The primary outcome is total mortality expressed as a hazard ratio. For dichotomous outcomes, the
estimates of effect of an intervention were expressed as risk ratios together with 95% confidence intervals. Dichotomous data were only
used for primary outcomes where hazard ratios were unavailable or could not be calculated.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Lymph Node Excision [methods; mortality]; Disease-Free Survival; Mouth Neoplasms [mortality; ∗surgery]; Oropharyngeal Neo-
plasms [mortality; ∗surgery]; Randomized Controlled Trials as Topic; Surgical Procedures, Elective [methods; mortality]
MeSH check words
Humans
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